Key Points
- Insider sale: Mo Qatanani sold 8,484 shares on Feb 23 at $47.07 for $399,341.88, trimming their position to 98,445 shares (a 7.93% reduction) after several prior sales including a 136,462-share sale on Dec 4 for ~$6.17M.
- Stock and analyst snapshot: SRRK traded near $45.39 with a market cap of about $4.63B and a one-year high of $49.82, and analysts hold a consensus "Buy" rating with an average price target of $51.14.
- Institutional ownership and flows: Approximately 91.08% of the stock is institutionally owned, with recent stake increases reported from AQR, Millennium, UBS and others, signaling notable institutional inflows despite insider selling.
Scholar Rock Holding Corporation (NASDAQ:SRRK - Get Free Report) insider Mo Qatanani sold 8,484 shares of Scholar Rock stock in a transaction on Monday, February 23rd. The shares were sold at an average price of $47.07, for a total value of $399,341.88. Following the completion of the transaction, the insider owned 98,445 shares in the company, valued at approximately $4,633,806.15. The trade was a 7.93% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.
Mo Qatanani also recently made the following trade(s):
- On Tuesday, February 17th, Mo Qatanani sold 7,989 shares of Scholar Rock stock. The shares were sold at an average price of $46.53, for a total value of $371,728.17.
- On Thursday, January 22nd, Mo Qatanani sold 14,898 shares of Scholar Rock stock. The stock was sold at an average price of $46.71, for a total value of $695,885.58.
- On Friday, January 16th, Mo Qatanani sold 8,406 shares of Scholar Rock stock. The shares were sold at an average price of $44.48, for a total transaction of $373,898.88.
- On Wednesday, January 14th, Mo Qatanani sold 13,112 shares of Scholar Rock stock. The shares were sold at an average price of $45.20, for a total transaction of $592,662.40.
- On Thursday, December 4th, Mo Qatanani sold 136,462 shares of Scholar Rock stock. The shares were sold at an average price of $45.21, for a total transaction of $6,169,447.02.
Scholar Rock Price Performance
Shares of NASDAQ SRRK traded down $1.59 during midday trading on Thursday, reaching $45.39. 150,807 shares of the company were exchanged, compared to its average volume of 951,627. The stock's 50-day moving average price is $45.31 and its 200-day moving average price is $38.68. The stock has a market cap of $4.63 billion, a P/E ratio of -14.40 and a beta of 0.67. The company has a quick ratio of 6.30, a current ratio of 6.30 and a debt-to-equity ratio of 0.41. Scholar Rock Holding Corporation has a one year low of $22.71 and a one year high of $49.82.
Institutional Inflows and Outflows
Hedge funds have recently made changes to their positions in the business. AQR Capital Management LLC grew its stake in Scholar Rock by 609.3% during the first quarter. AQR Capital Management LLC now owns 57,294 shares of the company's stock worth $1,842,000 after purchasing an additional 49,217 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Scholar Rock by 12.3% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 53,046 shares of the company's stock valued at $1,709,000 after acquiring an additional 5,831 shares during the period. Millennium Management LLC lifted its position in shares of Scholar Rock by 37.4% during the 1st quarter. Millennium Management LLC now owns 200,255 shares of the company's stock valued at $6,438,000 after acquiring an additional 54,555 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in Scholar Rock by 25.6% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 169,825 shares of the company's stock worth $5,460,000 after acquiring an additional 34,594 shares in the last quarter. Finally, Strs Ohio acquired a new stake in Scholar Rock in the first quarter worth $77,000. 91.08% of the stock is owned by institutional investors.
Analyst Ratings Changes
Several equities analysts have commented on the company. JPMorgan Chase & Co. increased their target price on Scholar Rock from $46.00 to $47.00 and gave the company an "overweight" rating in a research report on Tuesday, November 18th. UBS Group assumed coverage on shares of Scholar Rock in a report on Wednesday, January 7th. They issued a "buy" rating and a $60.00 price objective for the company. Citigroup began coverage on shares of Scholar Rock in a report on Friday, January 9th. They set a "buy" rating and a $55.00 target price on the stock. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Scholar Rock in a research note on Thursday, December 11th. Finally, BMO Capital Markets reiterated an "outperform" rating and set a $50.00 price target on shares of Scholar Rock in a report on Friday, November 14th. Four equities research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Buy" and an average price target of $51.14.
Read Our Latest Analysis on Scholar Rock
Scholar Rock Company Profile
(
Get Free Report)
Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company's research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock's approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.
The company's lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
